CLINICAL TRIALS PROFILE FOR ESTRACE

All Clinical Trials for ESTRACE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00114517 ↗	ELITE: Early Versus Late Intervention Trial With Estradiol	Completed	National Institute on Aging (NIA)	Phase 2/Phase 3	2004-07-01	The purpose of this study is to examine the effects of oral 17B-estradiol (estrogen) on the progression of early (subclinical) atherosclerosis and cognitive decline in healthy postmenopausal women.
NCT00114517 ↗	ELITE: Early Versus Late Intervention Trial With Estradiol	Completed	University of Southern California	Phase 2/Phase 3	2004-07-01	The purpose of this study is to examine the effects of oral 17B-estradiol (estrogen) on the progression of early (subclinical) atherosclerosis and cognitive decline in healthy postmenopausal women.
NCT00115024 ↗	EPAT: Estrogen in the Prevention of Atherosclerosis Trial	Completed	Mead Johnson Nutrition	Phase 2/Phase 3	1994-04-01	The purpose of this study is to determine the effects of estrogen replacement therapy (ERT) on the progression of early atherosclerosis in healthy postmenopausal women without preexisting cardiovascular disease (CVD).
NCT00115024 ↗	EPAT: Estrogen in the Prevention of Atherosclerosis Trial	Completed	National Institute on Aging (NIA)	Phase 2/Phase 3	1994-04-01	The purpose of this study is to determine the effects of estrogen replacement therapy (ERT) on the progression of early atherosclerosis in healthy postmenopausal women without preexisting cardiovascular disease (CVD).
NCT00465894 ↗	Detrol Long Acting (LA) vs Estrace Vaginal Cream for the Treatment of Overactive Bladder Symptoms	Completed	Pfizer	N/A	2007-04-01	The purpose of this study is to determine if long acting tolterodine confers more benefit than intravaginal low dose estrogen in the treatment of Overactive Bladder Syndrome at 12 weeks post-treatment initiation. The hypothesis is that low dose intra-vaginal estrogen confers greater benefit than tolterodine in the treatment of Overactive Bladder symptoms. Secondary outcomes were to assess if the addition of the other therapy to the treatment regimen conferred benefit at 24 weeks and 52 weeks.
NCT00465894 ↗	Detrol Long Acting (LA) vs Estrace Vaginal Cream for the Treatment of Overactive Bladder Symptoms	Completed	University of Alabama at Birmingham	N/A	2007-04-01	The purpose of this study is to determine if long acting tolterodine confers more benefit than intravaginal low dose estrogen in the treatment of Overactive Bladder Syndrome at 12 weeks post-treatment initiation. The hypothesis is that low dose intra-vaginal estrogen confers greater benefit than tolterodine in the treatment of Overactive Bladder symptoms. Secondary outcomes were to assess if the addition of the other therapy to the treatment regimen conferred benefit at 24 weeks and 52 weeks.

Clinical Trial Conditions for ESTRACE

Condition Name

Condition Name for ESTRACE
Intervention	Trials
Atrophic Vaginitis	3
PTSD	2
Menopause	2
Atherosclerosis	2

Condition MeSH

Condition MeSH for ESTRACE
Intervention	Trials
Atrophy	7
Vaginitis	4
Breast Neoplasms	4
Syndrome	3

Clinical Trial Locations for ESTRACE

Trials by Country

Trials by Country for ESTRACE
Location	Trials
United States	113
Canada	1
Chile	1

Trials by US State

Trials by US State for ESTRACE
Location	Trials
California	8
Florida	7
Pennsylvania	7
Virginia	6
North Carolina	6

Clinical Trial Progress for ESTRACE

Clinical Trial Phase

Clinical Trial Phase for ESTRACE
Clinical Trial Phase	Trials
Phase 4	6
Phase 3	9
Phase 2/Phase 3	2

Clinical Trial Status

Clinical Trial Status for ESTRACE
Clinical Trial Phase	Trials
Completed	17
Not yet recruiting	7
Recruiting	5

Clinical Trial Sponsors for ESTRACE

Sponsor Name

Sponsor Name for ESTRACE
Sponsor	Trials
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	3
NYU Langone Health	3
University of Virginia	3

Sponsor Type

Sponsor Type for ESTRACE
Sponsor	Trials
Other	36
Industry	15
NIH	10